# Electra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/electra-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.electra-therapeutics.com/
- Total disclosed funding: $218M
- Latest round: Series C (Oct 15, 2025)
- Investors on record: 13

## About

Based in California, US, and founded in 2018, Electra Therapeutics, Inc., aka Electra Therapeutics operates as a biotechnology company, focused on the development of novel drugs, intended to target SIRP (signal regulatory proteins), and thereby assist in the treatment of various diseases. In October 2025, Electra Therapeutics, Inc. raised USD 134.19 million in series C funding co-led by new investors EQT Life Sciences and Nextech, with participation from other new investors Sanofi, HBM Partners, and Mubadala Capital. Returning investors OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, and RA Capital Management and other unspecified investors also participated in the round.

Electra Therapeutics, Inc. engages in the development of a pipeline of antibody therapies, that targets specific SIRP (a class of cell surface receptors) proteins to eliminate the pathological immune cells, which causes various conditions including cancer and immunological illnesses. The company’s main product namely ELA026 (currently in Phase 1 clinical-stage), is a novel therapy developed for the treatment of a fatal hyperinflammatory condition called secondary hemophagocytic lymphohistiocytosis (sHLH).

The company will use the October 2025 funding to run a Phase 2/3 clinical trial for its lead drug targeting sHLH, expand into blood cancers, and advance a second immunology program.

## Funding rounds

- Series C, Oct 15, 2025, $134M — OrbiMed Advisors, HBM Partners, EQT Life Sciences, New Leaf Venture Partners, Nextech, Redmile Group, Sanofi, RA Capital Management, Cormorant Asset Management, Mubadala Capital, Westlake Village BioPartners, Blue Owl
- Series B, Feb 9, 2022, $84M — OrbiMed Advisors, New Leaf Venture Partners, Redmile Group, RA Capital Management, Cormorant Asset Management, Westlake Village BioPartners, Cowen Healthcare Investments

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series B, Series C
- Cowen Healthcare Investments — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series C
- Sanofi — Series C
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series C
- Blue Owl (https://capitalatlas.ai/funds/blue-owl) — Series C